-

Favorable Clinical Data for Applaud Medical’s Novel Technology for Treating Urinary Stones Presented During the 2024 AUA Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Applaud Medical, an emerging leader in the treatment of urinary stones, today announced positive results from a prospective, multicenter study of the company’s BRIO Enhanced Lithotripsy System (ELS) for the treatment of obstructive ureteral stones. The results were presented as a podium presentation during the American Urological Association's (AUA) 2024 Annual Meeting held in San Antonio, Texas. The study combined Applaud Medical’s proprietary acoustically enhanced microbubbles with a low-pressure ultrasound system to treat ureteral stones. When assessed by CT-scan 30 days following the procedure, 72% of the patients who underwent the treatment had no urinary stone fragment greater than 3 millimeters following a single treatment.

“Our study provided initial clinical data demonstrating the safety and efficacy of acoustic cavitation lithotripsy for the treatment ureteral stone disease,” stated Scott Wiener, MD, Assistant Professor of Urology and Director of the Kidney Stone Program at SUNY Upstate Medical University in Syracuse, New York. “The single treatment stone free rate we observed in this study exceeded that previously reported for both the spontaneous passage of ureteral stones (adjusted for size and location), as well as shockwave lithotripsy of ureteral stones. These data provide the foundation for further clinical research using this exciting new approach to urinary stone management.”

“The currently available options for treatment of urinary stones often require patients to wait extended periods of time prior to obtaining surgical treatment while enduring both the pain and disruption to their lives,” said Paul Molloy, CEO of Applaud Medical. “We are developing the BRIO System to change the standard of care, combining our patented calcium-seeking microbubbles with our proprietary low-pressure ultrasound console and ultrasound beam sensing catheter to treat patients suffering with urinary stone disease. Our solution aims to eliminate ureteral stones quickly, affordably, and without general anesthesia or fluoroscopy, bringing it to a physician’s office and other non-hospital settings.”

About Applaud Medical

Applaud Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

For more information, visit www.applaudmedical.com/

Contacts

Paul Molloy
Chief Executive Officer
Applaud Medical, Inc.
Email: paul.molloy@applaudmedical.com
Tel: (415) 887-2037

Applaud Medical


Release Summary
Favorable Clinical Data for Applaud Medical’s Novel Technology for Treating Urinary Stones Presented During the 2024 AUA Annual Meeting
Release Versions

Contacts

Paul Molloy
Chief Executive Officer
Applaud Medical, Inc.
Email: paul.molloy@applaudmedical.com
Tel: (415) 887-2037

Social Media Profiles
More News From Applaud Medical

Avvio Medical Receives FDA Breakthrough Device Designation for the Avvio Enhanced Lithotripsy System (ELS)

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company developing next-generation kidney stone treatment technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the Avvio Enhanced Lithotripsy System (ELS). The designation highlights the system’s potential to improve outcomes, reduce complications, and expand access to minimally invasive, anesthesia-sparing kidney stone care for mill...

Avvio Medical Announces New CPT Code for Its Breakthrough Kidney Stone Treatment Technology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a company dedicated to revolutionizing the treatment of urinary stones, is excited to announce that the American Medical Association (AMA) has officially published the early release of a new Category III CPT code for Avvio’s novel kidney stone treatment system. Effective January 1, 2026, CPT code 0991T will be used by healthcare providers and facilities nationwide to report procedures utilizing Avvio Medical’s innovative technology. The new c...

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include:...
Back to Newsroom